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Abstract	
Breast	cancer	is	the	commonest	form	of	cancer	in	women,	but	successful	treatment	is	
confounded	by	the	heterogeneous	nature	of	breast	tumours:	Effective	treatments	exist	for	
hormone-sensitive	tumours,	but	triple-negative	breast	cancer	results	in	poor	survival.	An	
area	of	increasing	interest	is	metabolic	reprogramming,	whereby	drug-induced	alterations	in	
the	metabolic	landscape	of	a	tumour	slow	tumour	growth	and/or	increase	sensitivity	to	
existing	therapeutics.	Nuclear	receptors	are	transcription	factors	central	to	the	expression	
of	metabolic	and	transport	proteins,	and	thus	represent	potential	targets	for	metabolic	
reprogramming.	We	show	that	activation	of	the	nuclear	receptor	FXR,	either	by	its	
endogenous	ligand	CDCA	or	the	synthetic	GW4064,	leads	to	cell	death	in	four	breast	cancer	
cell	lines	with	distinct	phenotypes:	MCF-10A	(normal),	MCF-7	(receptor	positive),	MDA-MB-
231	and	MDA-MB-468	(triple	negative).	Furthermore,	we	show	that	the	mechanism	of	cell	
death	is	predominantly	through	the	intrinsic	apoptotic	pathway.	Finally,	we	demonstrate	
that	FXR	agonists	do	not	stimulate	migration	in	breast	cancer	cell	lines,	an	important	
potential	adverse	effect.	Together,	our	data	support	the	continued	examination	of	FXR	
agonists	as	a	novel	class	of	therapeutics	for	the	treatment	of	breast	cancer.		
	
Keywords:	Apoptosis,	Autophagy,	Nuclear	Receptor,	Triple	negative	breast	cancer,	Bile	
acids,		
	
Abbreviations:	CDCA	=	chenodexoycholic	acid;	ER	=	estrogen	receptor;	FXR	=	Farnesoid	X-
receptor;	Her2	=	Human	epidermal	growth	factor	receptor	2;	PR	=	progesterone	receptor;	
TNBC	=	Triple	negative	breast	cancer	
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1.! Introduction	
Breast	cancer	represents	one	of	the	largest	killers	of	women	in	the	Western	world,	with	a	
lifetime	risk	of	one	in	eight	[1].	In	the	past	decades	a	number	of	successful	therapeutics	
targeting	breast	cancer	have	been	developed,	used	in	both	single	and	combination	
therapies.	However,	improvements	in	the	five	year	survival	rate	have	not	been	as	high	as	
hoped.	This	is	to	a	large	degree	due	to	the	heterogeneous	nature	of	breast	tumours,	with	
multiple	molecular	landscapes	being	classified	as	a	single	disease.	These	diverse	tumour	
phenotypes	result	in	varied	responses	to	therapeutic	intervention,	often	leading	to	sub-
optimal	patient	response	[2].	To	aid	optimisation	of	treatment	regimens,	breast	tumours	are	
commonly	classified	into	three	clinically	significant	groups:	hormone	sensitive,	Her2	positive	
and	triple	negative	breast	cancers	(TNBC)	[3].	Both	hormone	sensitive	and	Her2-positive	
tumours	have	a	range	of	good	therapeutic	options,	but	TNBC	tumours	are	characterized	by	
a	lack	of	molecular	targets	and	tendency	to	develop	drug	resistance.	Not	surprisingly,	TNBC	
represents	the	leading	cause	of	death	in	breast	cancer	[4].	It	is	thus	imperative	to	develop	
novel	therapeutic	options	that	would	exploit	tumour	vulnerabilities,	mitigate	drug	
resistance	and	lead	to	improved	patient	response,	and	especially	in	the	case	of	TNBC	
tumours.	
Two	areas	of	therapeutic	intervention	have	received	increasing	attention	in	the	past	few	
years:	Synthetic	lethality	and	metabolic	vulnerability.	These	related	concepts	exploit	the	
greater	understanding	of	network	biology	to	predict	synergistic	combination	therapies	[5].	
In	synthetic	lethality,	the	concept	of	‘rescue	pathways’	is	exploited:	In	essence,	targeting	of	
a	single	species	in	a	biological	pathway	is	often	negated	by	re-routing	of	the	biological	
network	to	exploit	a	secondary	pathway.	In	synthetic	lethality,	drug	combinations	are	used	
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to	target	both	the	primary	and	secondary	pathways,	producing	a	synergistic	cytotoxicity	[6].	
In	metabolic	vulnerability,	this	theory	of	network	targeting	is	further	expanded,	looking	for	
novel	agents	that	will	work	with	existing	therapeutics.	Tumour	cells	have	a	high	metabolic	
load,	due	to	their	requirement	to	make	all	the	precursors	required	for	constant	cell	
proliferation	[7].	As	such,	the	development	of	drugs	that	target	metabolism	may	reduce	cell	
proliferation,	and	synergise	with	existing	drugs	to	produce	more	effective	combination	
therapies	[8].		
Members	of	the	nuclear	receptor	family	of	ligand-activated	transcription	factors	generally	
regulate	expression	of	genes	that	encode	proteins	involved	in	metabolic	and	transport	
processes	[9].	As	such,	they	may	represent	important	targets	to	instigate	metabolic	
reprogramming	of	tumour	cells,	leading	to	a	reduction	in	supply	of	the	components	
required	for	cell	growth	[10].	Nuclear	receptor	expression	is	widespread	throughout	the	
body	[11],	with	a	number	being	(over)expressed	in	breast	tumours	[12].	Indeed,	two	of	the	
three	major	classifiers	for	breast	cancer,	the	estrogen	receptor	(ER;	NR3A1)	and	the	
progesterone	receptor	(PR;	NR3C3),	are	nuclear	receptors,	and	disruption	of	their	regulatory	
action	is	a	successful	treatment	in	receptor	positive	tumours	[13,	14].	The	farnesoid	X-
receptor	(FXR;	NR1H4)	is	an	adopted	nuclear	receptor	with	oxysterols	such	as	primary	and	
secondary	bile	acids	as	its	endogenous	ligands	[15,	16].	Bile	acids	are	the	metabolic	products	
of	cholesterol,	and	can	be	toxic	to	the	body	at	high	concentrations.	FXR	acts	to	prevent	
accumulation	of	bile	acids	by	inducing	expression	of	a	second	nuclear	receptor	small	
heterodimer	partner	(SHP,	NR0B2),	which	inhibits	expression	of	CYP7A1,	the	rate-limiting	
enzyme	in	bile	acid	synthesis	[17,	18].	The	main	site	of	bile	acid	production	and	secretion	
are	the	liver	and	intestine,	respectively,	and	this	is	mirrored	by	high	levels	of	FXR	expression	
in	these	organs	[19].	However,	as	approximately	70%	of	bile	acids	are	re-absorbed	by	the	
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body,	they	can	reach	micromolar	concentrations	in	the	plasma,	which	may	underlie	the	
expression	of	FXR	in	a	number	of	other	tissues	[20].	FXR	has	been	shown	to	be	expressed	in	
both	normal	breast	tissue	and	breast	tumours,	with	its	activation	in	vitro	stimulates	
apoptosis	and	inhibits	aromatase	[21].	These	features	suggest	that	FXR	agonists	may	
represent	a	novel	class	of	breast	cancer	therapeutics	due	to	their	ability	to	alter	the	FXR-
regulated	metabolic	network.		
In	the	present	work,	we	first	fully	delineate	the	molecular	mechanisms	by	which	FXR	
agonists	activate	apoptosis	in	breast	cancer	cell	lines,	demonstrating	this	to	be	through	the	
intrinsic	pathway.	Next,	we	examine	the	ability	of	FXR	agonists	to	stimulate	migration	in	
these	cell	lines,	concluding	that	they	do	not	possess	this	ability.	Together,	these	data	
support	the	further	examination	of	FXR	agonists	as	cancer	chemotherapeutics.	
	
2.! Materials	and	Methods	
2.1.! Materials		
The	breast	tumour	cell	line	MDA-MB-468	(ATCC-HTB-132),	and	the	normal	breast	cell	line	
MCF10A	(ATCC-CRL-10317)	were	purchased	from	the	ATCC	(Teddington,	UK),	while	the	
breast	tumour	cell	lines	MCF-7	(ECACC	86012803)	and	MDA-MB-231		(ECACC	92020424)	
were	purchased	from	the	ECACC	(Porton	Down,	UK).	CDCA	and	GW4064	were	purchased	
from	Sigma	Aldrich	(Poole,	UK)	and	Tocris	Biosciences	(Abingdon,	UK),	respectively.		
2.2.! Cell	Culture	
MCF7,	MDA-MB-468	and	MDA-MB-231	cells	were	grown	in	Dulbecco’s	modified	eagle	
medium	(DMEM)	with	phenol	red	and	L-glutamine,	supplemented	with	10%	foetal	bovine	
serum,	100	units/ml	penicillin,	0.1mg/ml	streptomycin	sulphate,	and	0.25µg/ml	
amphotericin	B.	MCF10A	cells	were	cultured	in	Dulbecco’s	modified	eagle	medium/F12	(1:1	
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v/v	DMEM/F12)	with	phenol	red,	supplemented	with	5%	horse	serum,	100	ng/ml	cholera	
toxin,	0.5	µg/ml	hydrocortisone,	10	µg/ml	insulin,	20	ng/ml	epidermal	growth	factor,	100	
µg/ml	streptomycin,		and	100	units/ml	penicillin.	
2.3.! Viability	Assay	
Cell	viability	was	assessed	by	the	3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl	tetrazolium	
bromide	(MTT)	assay,	as	previously	described	[22].	Briefly,	breast	cancer	cell	lines	were	
plated	in	96-well	tissue	culture	flasks	at	a	density	of	5	x	10
4
	cells	per	well,	and	allowed	to	
attach	overnight.	For	experiments	using	serum-starved	conditions,	cells	were	grown	for	a	
further	24	hours	in	serum-free	medium.	Next,	cells	were	exposed	to	test	chemicals	for	the	
required	time;	during	the	final	60	min	of	incubation,	0.5	mg/mL	MTT	was	added.	At	the	end	
of	the	incubation	period,	the	resultant	formazan	salt	was	dissolved	in	DMSO	and	its	
absorbance	measured	at	540	nm.	Results	are	expressed	as	a	percentage	of	vehicle	control;	
each	data	point	represents	the	mean	of	a	minimum	of	three	independent	experiments	of	6	
wells	per	experiment,	with	error	bars	representing	the	standard	error	of	the	mean	(SEM).	
2.4.! Caspase	Analysis	
Caspase	activity	was	measured	using	the	Caspase-Glo	assay	system	(Promega,	UK)	as	
previously	reported	[23].	Briefly,	breast	cancer	cell	lines	were	seeded	in	96-well	plates	at	a	
density	of	1	x	10
4
	cells	per	well,	allowed	to	attach	overnight,	serum-starved	for	24	hours,	
and	then	exposed	to	test	chemicals	(±	specific	caspase	inhibitor)	as	required.	Next,	Caspase-
Glo	reagent	was	added,	mixed,	incubated	at	room	temperature	for	one	hour,	and	then	
luminescence	measured.	Results	are	expressed	as	a	percentage	of	vehicle	control;	each	data	
point	represents	the	mean	of	a	minimum	of	three	independent	experiments	of	6	wells	per	
experiment,	with	error	bars	representing	the	standard	error	of	the	mean	(SEM).	
2.5.! Protein	Analysis	
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Western	blot	analysis	was	undertaken	as	previously	described	[22].	Briefly,	total	protein	was	
extracted	using	RIPA	buffer,	and	protein	quantified	by	the	method	of	Smith	[24]	.	Thirty	
micrograms	of	total	protein	was	separated	on	precast	6-18%	polyacrylamide	gels,	and	then	
transferred	to	PVDF	membrane.	Protein	were	detected	overnight	at	4˚C	using	the	following	
primary	antibodies	and	dilutions:	FXR	1:500	(sc13063,	Santa	Cruz	Biotechnology);	MMP2	
1:200	(sc-10736,	Santa	Cruz	Biotechnology);	MMP9	1:200	(sc-10737,	Santa	Cruz	
Biotechnology);	PARP	1:1000	(#9542,	Cell	Signalling);	cytochrome	c	1:500	(sc-7159,	Santa	
Cruz	Biotechnology);	Bax	1:250	(sc-493,	Santa	Cruz	Biotechnology);	Bcl2	1:250	(sc-7382,	
Santa	Cruz	Biotechnology);	SHP	1:250	(sc-15283,	Santa	Cruz	Biotechnology);	LC3	1:1000	
(#2775,	Cell	Signalling);	and,	B-actin	1:2,000	(A2228,	Sigma-Aldrich).	Next,	membranes	were	
incubated	with	an	IRDye	800	CW	goat,	anti-rabbit	secondary	antibody	(1:10,000)	for	one	
hour	at	room	temperature,	and	imaged	using	an	Odyssey	CLx	infrared	imaging	system	(LI-
COR	Biosciences).	
2.6.! Autophagy	Analysis	
In	addition	to	examination	of	autophagy	through	Western	blotting	of	LC3	cleavage	(see	
above),	the	accumulation	of	was	p62/SQSTM1	in	autophagosomes	was	quantified	using	the	
Premo	Autophagy	Sensor	GFP-p62	assay	(Molecular	Probes,	OR,	USA)	[25].	Breast	cancer	
cell	lines	were	seeded	in	24-well	plates	at	a	density	of	2	x	10
5
	cells	per	well,	allowed	to	
attach	overnight,	exposed	to	pGFP-62	induction	mix	in	serum-free	medium	for	24	hours,	
and	then	exposed	to	test	chemicals	as	required.	p62/SQSTM1	fluorescence	was	quantified	
and	expressed	as	a	percentage	of	vehicle	control;	each	data	point	represents	the	mean	of	a	
minimum	of	three	independent	experiments,	with	error	bars	representing	the	standard	
error	of	the	mean	(SEM).	3-methyladenine	and	rapamycin	(Sigma-Aldrich)	were	used	as	
inhibitors	and	activators	of	autophagy,	respectively	[26-28].		
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2.7.! Cell	Migration	Analysis	
For	the	transwell	assay,	24-well	transwell	inserts	with	an	8	μm	pore	size	(Corning	Inc,	USA)	
were	used.	Breast	cancer	cell	lines	were	seeded	into	the	upper	chamber	at	a	density	of	
1x10
5
	cells	per	well	in	serum-free	medium.	Plates	were	incubated	24	-72	hours,	and	then	
cells	in	the	lower	chamber	counted;	to	ensure	counting	of	all	migrated	cells,	the	lower	
surface	of	the	transwell	was	exposed	to	1x	trypsin:EDTA	for	30	minutes.		
For	the	wound-healing	assay,	35	mm	wound	healing-	inserts	(Ibidi,	Martinsried,	Germany)	
were	used.	Breast	cancer	cell	lines	were	seeded	into	the	chamber	at	a	density	of	1x10
5
	cells	
per	well	in	serum-free	medium	and	allowed	to	attach	overnight.	Inserts	were	removed,	and	
gap	closure	measured	at	time	0	and	12	hours	after	exposure	to	test	chemical	using	tScratch	
program	[29].	
2.8.! Inhibition	of	FXR	activity	by	FXR	dominant-negative	over-expression	
To	demonstrate	that	the	observed	effects	were	FXR-dependent,	experiments	were	
undertaken	using	over-expression	of	a	dominant	negative	FXR	mutant	[30].	MCF-7	and	
MDA-MB-231	cells	were	transfected	with	the	FXR-DN	expressing	plasmid	using	Fugene	6	
(Promega,	UK)	according	to	the	manufacturer’s	instruction,	and	incubated	overnight	to	
allow	protein	expression.	Cells	were	then	exposed	to	GW4064	and	analysed	as	previously	
described.		
2.9.! Statistical	Analysis	
Statistical	analysis	was	undertaken	using	GraphPad	Prism	v6.01	(GraphPad	Software	Inc.,	La	
Jolla,	USA).	Datasets	were	compared	through	either	a	one-way	ANOVA	with	Tukey’s	
multiple	comparison	test	or	a	two-way	ANOVA	with	Sidak’s	multiple	comparison	test,	as	
appropriate.	The	level	of	statistical	significance	was	set	a	priori	at	p	<	0.05.	
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3.! Results	and	Discussion	
3.1.! Activation	of	FXR	induces	cell	death	in	breast	cancer	cell	lines	
The	nuclear	receptor	FXR	is	classically	associated	with	bile	acid	homeostasis	in	the	body	and	
its	target	genes	impact	on	the	metabolic	and	transporter-mediated	clearance	of	both	bile	
acids	and	their	precursors	[15].		However,	FXR	activation	has	also	been	reported	to	elicit	a	
number	of	other	phenotypes,	including	cell	death.	To	confirm	this	phenotype	in	breast	
cancer	cell	lines,	we	examined	the	effect	of	the	endogenous	ligand	CDCA	and	the	more	
potent	and	selective	artificial	ligand	GW4064	[31].	Four	cell	lines	were	chosen	to	represent	
different	breast	cancer	phenotypes:	normal	(i.e.	MCF-10A),	receptor	positive	tumour	(i.e.	
MCF-7)	and	triple	negative	tumours	(i.e.	MDA-MB-231	and	MDA-MB-468).	We	confirmed	
that	FXR	is	expressed	in	these	cell	lines,	and	for	MCF-7	and	MDA-MB-231	cells	that	the	FXR-
dependent	signalling	cascade	is	intact,	with	activation	of	SHP	expression	in	response	to	FXR	
activation	(supplemental	figure	S1).	
Both	CDCA	and	GW4064	caused	a	concentration-dependent	toxicity	in	all	cell	lines	(Figure	
1),	with	the	effect	generally	being	more	marked	in	serum-free	conditions.	This	is	consistent	
with	the	observation	that	both	CDCA	and	GW4064	are	lipophilic,	with	LogP	values	of	4.15	
and	8.3,	respectively	[20].	In	serum-containing	medium,	the	free	concentration	of	both	
compounds	are	expected	to	be	reduced	due	to	protein	binding	[32].	IC50	values	were	
determined	for	all	conditions	and	are	presented	in	Table	1.	We	note	that,	as	expected,	IC50	
values	for	GW4064	are	approximately	three	orders	of	magnitude	lower	than	for	CDCA,	
consistent	with	the	higher	affinity	of	this	ligand	for	FXR	[GW4064	Kd=0.01μM	versus	CDCA	
Kd=50μM	[15,	31]].	Data	consistent	with	these	values	were	also	obtained	with	MTT	analysis	
following	72	hours	of	exposure	of	cell	lines	to	each	compound	(data	not	shown).	
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Despite	the	diverse	phenotypes	of	the	four	cell	lines	studied,	all	responded	in	the	same	
manner	to	CDCA	and	GW4064,	both	qualitatively	and	quantitatively,	with	no	statistically	
significant	differences	in	response	for	either	agonist	between	cell	lines.	This	would	suggest	
that	FXR-dependent	cytotoxicity	is	a	general	cell	response,	and	not	dependent	of	any	
emergent	phenotypic	property	of	the	different	genotypes	of	each	cell	line.		
3.2.! FXR-mediated	cytotoxicity	is	mediated	through	the	intrinsic	apoptotic	cascade	
Having	determined	that	FXR	agonists	stimulate	cytotoxicity	in	all	four	breast	cancer	cell	
lines,	we	next	examined	the	molecular	mechanisms	underlying	this	response	in	the	receptor	
positive	MCF-7	and	triple	negative	MDA-MB-231	cell	lines.		
Activation	of	FXR	has	been	previously	reported	to	cause	apoptotic	cell	death	in	breast	
cancer	MCF-7	and	MDA-MB-468	cell	lines	[21].	As	depicted	in	Figure	2,	exposure	of	MCF-7	
and	MDA-MB-231	cells	to	GW4064	or	CDCA	for	24	hours	resulted	in	a	statistically	significant	
activation	of	the	executioner	caspases	3/7,	and	cleavage	of	its	substrate	poly(ADP-
ribose)polymerase-1		(PARP)	[33].	This	confirms	the	data	of	Swales	et	al,	and	extends	it	to	
cover	another	triple	negative	cell	line.	In	addition,	we	note	Swales	et	al	used	high	
concentrations	of	GW4064	(30µM;	3,000	x	Kd);	here	we	use	a	lower	concentration	that	will	
cause	99.9%	receptor	occupancy	while	reducing	the	risk	of	off-target	effects	[31].	FXR	
agonist-mediated	activation	of	caspases	3/7,	and	subsequent	PARP	cleavage,	is	more	potent	
in	the	MDA-MB-231	cell	line	compared	to	the	MCF-7	cell	line.	This	is	consistent	with	reports	
that	the	MCF-7	cell	line	lacks	expression	of	caspase	3	[34,	35],	meaning	only	caspase	7	
activity	is	present.	
Having	confirmed	that	FXR	activation	by	GW4064	or	CDCA	causes	apoptosis	in	breast	cancer	
cell	lines,	we	next	examined	the	molecular	mechanism(s)	underlying	this	effect.	The	
apoptotic	cascade	can	occur	through	the	intrinsic	and	extrinsic	pathways,	with	each	being	
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composed	of	distinct	molecular	events	that	converge	at	the	activation	of	executioner	
caspases	such	as	caspase	3	and	7	[36].	Caspase	8	activation	is	classically	associated	with	the	
extrinsic	apoptotic	pathway,	while	caspase	9	activation	is	indicative	of	apoptosis	via	the	
intrinsic	pathway.	Exposure	of	MCF-7	and	MDA-MB-231	cells	to	either	3µM	GW4064	or	
30µM	CDCA	for	9	hours	caused	a	statistically	significant	increase	in	caspase	9	activity,	which	
could	be	prevented	by	co-incubation	with	the	caspase-9	inhibitor	Z-LEHD-FMK	(Figure	3a).	
Fold	increases	in	caspase	9	activity	were	the	same	order	of	magnitude	as	that	observed	with	
the	positive	control,	1µM	staurosporine.	In	contrast,	neither	compound	was	able	to	activate	
caspase	8	activity	in	either	MCF-7	or	MDA-MB-231	cell	lines	(Figure	3b);	presence	of	a	
functional	extrinsic	pathway	was	demonstrated	through	the	use	of	the	positive	control	
chemical	Fas	ligand	[37].	Together,	these	data	are	consistent	with	activation	of	FXR	resulting	
in	cell	death	through	activation	of	the	intrinsic	pathway	of	apoptosis.		
To	confirm	the	ability	of	GW4064	and	CDCA	to	induce	intrinsic	pathway-mediated	apoptosis,	
we	examined	several	other	molecular	markers	for	this	pathway.	A	key	stage	in	the	intrinsic	
pathway,	and	one	that	distinguishes	it	from	the	extrinsic	pathway,	is	mitochondrial	
dysfunction.	Members	of	the	BCL2	family	are	central	regulators	of	this	process,	with	the	
relative	expression	of	pro-	(e.g.	Bcl2)	and	anti-	(e.g.	BAX)	apoptotic	family	members	
determining	cell	fate	[36].	Figure	4a	demonstrates	that	FXR	activation	results	in	a	significant	
increase	in	BAX:Bcl2	ratio,	with	GW4064	increasing	the	ratio	by	2.9±0.3-fold	and		4.8±1.0-
fold,	and	CDCA	by	2.8±0.4-fold	and	2.5±0.2-fold	in	MCF-7	and	MDA-MB-231	cells,	
respectively.	Alteration	in	this	ratio	is	associated	with	changes	in	mitochondrial	membrane	
integrity,	leading	to	cytochrome	c	release	into	the	cytoplasm,	which	complexes	with	Apaf-1	
to	form	the	apoptosome	[38].	We	observe	a	time-dependent	release	of	cytochrome	c	
following	exposure	of	MCF-7	and	MDA-MB-231	cells	to	both	GW4064	and	CDCA	(Figure	4b).		
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As	noted	above,	the	MCF-7	cell	line	may	have	limited	apoptotic	capacity	due	to	a	lack	of	
expression	of	caspase	3	[34,	35].	Under	such	conditions,	alternative	pathways	may	be	
initiated.	Autophagy	is	a	cell	rescue	pathway	involving	degradation	and	recycling	of	
damaged	cell	components	[39],	and	the	relative	roles	of	autophagy	and	apoptosis	in	
determining	cell	fate	appears	to	be	highly	context	dependent,	with	factors	including	cellular	
background,	type	of	perturbation,	and	degree	of	damage.		Conjugation	of	cytosolic	LC3-I	to	
phosphatidylethanolamine,	forming	autophagosomal	LC3-II	is	an	important	marker	of	
autophagy	[40],	and	in	Figure	5a	we	present	the	impact	of	GW4064	and	CDCA	on	the	LC3-
I:LC3-II	ratio	in	both	cell	lines.	In	MCF-7	cells,	GW4064	is	observed	to	cause	a	4.4±0.3-fold	
increase	in	this	ratio,	consistent	with	activation	of	the	autophagy	pathway,	but	CDCA	does	
not	elicit	a	similar	response.	In	MDA-MB-231	cells,	neither	compound	was	able	to	elicit	a	
significant	change	in	LC3-I:LC3-II.	A	second	experimental	approach	was	used	to	confirm	the	
activation	of	autophagy,	namely	accumulation	of	p62/SQSTM1,	a	ubiquitin-binding	protein	
that	targets	ubiquitinylated	proteins	for	degradation	via	autophagy	[41].		Both	3µM	
GW4064	and	30µM	CDCA	elicited	a	statistically	significant	increase	in	p62-GFP	fluorescence	
in	MCF-7	cells,	but	not	in	MDA-MB-231	cells.	This	increase	was	reduced	by	the	addition	of	
5mM	3-methyladenine,	an	inhibitor	of	autophagy.	Assay	specificity	was	demonstrated	by	
the	positive	control	compound	2.5µM	rapamycin	[26].				
These	data	are	consistent	with	MCF-7	cells	using	the	autophagic	response	as	a	complement	
to	apoptosis,	which	is	necessary	due	to	the	compromised	capacity	to	undergo	apoptosis	
caused	by	lack	of	expression	of	the	executioner	caspase	3.	In	support	of	this,	when	
autophagy	is	inhibited	by	3-methyladenine,	no	significant	increase	in	caspase	3/7	activation	
is	seen	in	MCF-7	cells,	suggesting	that	the	cells	are	already	utilising	the	caspase-dependent	
apoptotic	cell	death	pathway	at	close	to	its	capacity	(Figure	5c).		
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3.3.! Induction	of	apoptosis	and	autophagy	in	breast	cancer	cell	lines	is	FXR-dependent	
As	previously	noted,	while	GW4064	is	a	highly	selective	ligand	against	FXR,	the	actions	of	
CDCA	are	more	promiscuous.	It	is	thus	important	to	demonstrate	that	the	observed	effects	
are	mediated	via	FXR	and	not	an	alternate	mechanism.	To	examine	this,	we	have	used	a	
dominant	negative	FXR	mutant	(FXR-DN)	to	squelch	FXR-mediated	signalling	[21,	30,	42].	As	
can	be	seen	from	figure	6a,	transfection	of	the	FXR-DN	plasmid	into	MCF-7	and	MDA-MB-
231	cells	effectively	blocks	FXR-dependent	signalling,	as	evidenced	by	the	ablation	of	SHP	
induction,	a	classical	FXR	target	gene,	in	response	to	GW4064.		
Blockade	of	FXR	signalling	by	FXR-DN	also	reduces	GW4064	and	CDCA-dependent	cell	death	
(Figure	6b),	consistent	with	previous	reports	that	this	is	FXR	dependent	[21].	The	reduction	
in	cell	death	is	due	to	decreased	apoptosis	in	both	cell	lines,	as	evidence	by	reduced	
activation	of	the	execution	caspases	3/7	(Figure	6c).	As	previously	demonstrated,	MCF-7	
cells,	which	are	deficient	in	caspase-3,	are	also	stimulated	to	undergo	autophagy	by	
GW4064,	and	we	demonstrate	that	this	is	also	FXR-dependent,	being	reduced	in	the	
presence	of	the	FXR-DN	mutant	(figure	6d).	
Together,	these	data	strongly	support	that	the	observed	effects	are	mediated	through	the	
action	of	FXR,	and	not	via	another,	non-specific,	mechanism.	
	
3.4.! Activation	of	FXR	in	breast	cancer	cell	lines	does	not	cause	an	increase	in	cell	
migration	
The	data	presented	herein	supports	the	cytotoxic	potential	of	FXR	activation	in	breast	
cancer	cell	lines.	In	addition,	we	further	elucidate	the	molecular	mechanisms	underlying	
this,	which	are	through	the	programmed	apoptotic	and	autophagic	pathways.	As	such,	these	
data	would	support	the	potential	of	FXR	agonists	as	cancer	chemotherapeutic	agents.	
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However,	a	number	of	reports	have	suggested	that	activation	of	FXR	can	alter	the	
migration/invasion	phenotype	of	tumour	cells,	although	the	data	in	this	area	is	
controversial.	For	example,	Fukase	et	al.	have	reported	a	positive	action	on	migration	in	the	
Hep3B	hepatoma	cell	line	[43],	while	Strauch	et	al.	demonstrated	a	similar	effect	in	
intestinal	epithelial	cells	[44].	Conversely,	Zhang	et	al	reported	that	FXR	suppression	
promoted	proliferation	and	migration	of	HepG2	and	Hep3B	hepatoma	cell	lines	[45],	while	
Yoyo	et	al.	demonstrated	a	repressive	effect	on	vascular	smooth	muscle	cell	migration	[46].	
Any	potential	for	enhanced	cell	migration/invasion	is	a	major	liability	in	the	development	of	
a	therapeutic	agent,	and	we	therefore	examined	the	potential	of	GW4064	and	CDCA	to	
effect	migration	in	breast	cancer	cells.		
In	the	transwell	migration	assay	we	were	able	to	detect	a	significant	number	of	migrated	
cells	following	72	hours	incubation	for	both	MCF-7	and	MDA-MB-231	cell	lines,	important	as	
MCF-7	are	considered	poorly	invasive	[47].	Exposure	of	cells	in	the	upper	chamber	to	either	
3	µM	GW4064	or	30	µM	CDCA	throughout	the	incubation	period	did	not	result	in	any	
increase	in	migration	rates	(Figure	7a).	In	addition,	we	note	that	extension	of	the	incubation	
period	to	include	a	1-hour	pre-incubation	with	FXR	agonist	also	did	not	impact	upon	
migration	rates	(data	not	shown).	A	second	experimental	approach	was	also	used	to	
examine	migration,	the	scratch	assay.	Data	from	this	assay	was	consistent	with	the	transwell	
assay;	while	significant	migration	could	be	observed	over	the	24	hour	incubation	period,	
there	was	no	significant	increase	when	MCF-7	or	MDA-MB-231	cells	were	exposed	to	FXR	
agonists	(Figure	7b).			
This	data	appears	in	conflict	with	that	of	Silva	et	al,	who	demonstrated	that	the	secondary	
bile	acid	deoxycholate	could	induce	migration	of	MDA-MB-231,	but	not	MCF-7	cells	[48].	
However,	the	methodology	used	by	Silva	et	al	was	significantly	different	from	the	present	
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work,	and	only	the	secondary	bile	acid	deoxycholate	was	examined.	This	bile	acid	is	a	
product	of	bacterial	metabolism	of	CDCA,	and	at	the	concentration	used	likely	to	cause	both	
FXR-dependent	and	FXR-independent	effects	[49].		
Given	the	important	negative	liability	associated	with	any	pro-migratory	effect,	and	the	
conflicting	data	in	this	area,	we	also	examined	MCF10A	and	MDA-MB-468	cells	for	their	
migratory	response	upon	FXR	activation.	As	presented	in	supplementary	figure	S2,	no	
evidence	was	found	to	support	a	pro-migratory	phenotype	in	either	of	these	cell	lines.	As	
such,	these	data	support	the	notion	that	FXR	activation	in	breast	cancer	cell	lines	does	not	
enhance	migratory	potential.	This	suggests	that	any	interaction	between	FXR	and	cell	
migration/invasion	is	complex,	and	almost	certainly	context-dependent.		
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Table	1:	IC50	values	for	CDCA-	and	GW4064-elicited	cell	death	in	breast	cancer	cell	lines	
	 CDCA	 GW4064	
	 Complete	
medium	
Serum-free	
medium	
Complete	
medium	
Serum-free	
medium	
MCF-7	 n.d.	 244.7±9.5	µM	 10.6±2.6	µM	 12.6±2.8	µM	
MDA-MB-231	 n.d.	 273.3±32.2	µM	 9.5±3.9	µM	 3.7±3.3	µM	
MDA-MB-468	 n.d.	 188.5±124.4	µM	 n.d.	 4.8±1.4	µM	
MCF-10A	 n.d.	 142.0±87.4	µM	 2.6±2.6	µM	 3.8±1.1	µM	
	n.d.	=	not	determined	as	slope	did	not	converge	
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Figure	1:	The	FXR	agonists	GW4064	and	CDCA	cause	concentration-dependent	toxicity	in	
breast	cancer	cell	lines.	MCF-10A	(A),	MCF-7	(B),	MDA-MB-231	(C)	and	MDA-MB-468	(D)	
cells	were	exposed	to	varying	concentrations	of	GW4064	or	CDCA	in	complete	or	serum-free	
medium.	Following	48	or	72	hours	of	exposure,	cell	viability	was	assessed	by	MTT.	Each	data	
point	represents	the	mean	of	three	independent	experiments,	while	error	bars	represent	
the	standard	error	of	the	mean	(SEM).	*	=	p<0.05,	**	=	p<0.01,	***	=	p<0.001	
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Figure	2:	The	FXR	agonists	GW4064	and	CDCA	cause	concentration-dependent	activation	
of	caspase	3	and	caspase	7	in	the	MCF-7	and	MDA-MB-231	cell	lines.	(A)	MCF-7	and	MDA-
MB-231	cells	were	exposed	to	3µM	GW4064,	30µM	CDCA,	or	1µM	staurosporine	in	serum-
free	medium,	in	the	presence	or	absence	of	specific	caspase	inhibitors	for	24	hours,	and	
then	Caspase	3	and	caspase	7	activity	measured.	(B)	MCF-7	and	MDA-MB-231	cells	were	
exposed	to	indicated	concentrations	of	GW4064,	CDCA	or	staurosporine	in	serum-free	
medium	for	24	hours	and	then	poly(ADP-ribose)polymerase-1		(PARP)	cleavage	assessed	by	
Western	blot.	Each	data	point	represents	the	mean	of	three	independent	experiments,	
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while	error	bars	represent	the	standard	error	of	the	mean	(SEM).	*	=	p<0.05,	**	=	p<0.01,	
***	=	p<0.001	
	
	
Figure	3:	The	FXR	agonists	GW4064	and	CDCA	activate	caspase	9,	but	not	caspase	8,	
activity	in	the	MCF-7	and	MDA-MB-231	cell	lines.	MCF-7	and	MDA-MB-231	cells	were	
exposed	to	3µM	GW4064,	30	µM	CDCA	or	1µM	staurosporine	in	serum-free	medium	for	24	
hours,	and	then	Caspase	8	and	caspase	9	activity	measured.	Each	data	point	represents	the	
mean	of	three	independent	experiments,	while	error	bars	represent	the	standard	error	of	
the	mean	(SEM).	*	=	p<0.05,	**	=	p<0.01,	***	=	p<0.001	
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Figure	4:	The	FXR	agonists	GW4064	and	CDCA	stimulate	apoptosis	through	the	intrinsic	
pathway	in	MCF-7	and	MDA-MB-231	cell	lines.	MCF-7	and	MDA-MB-231	cells	were	
exposed	to	3µM	GW4064,	30	µM	CDCA	or	1µM	staurosporine	in	serum-free	medium.	(A)	
Subcellular	localisation	of	cytochrome	c	was	examined	following	0,	4,	6	and	8	hours	of	
exposure,	with	LDH	as	a	marker	for	the	cytosolic	fraction.	(B)	Bax	and	Bcl2	protein	levels	
were	measured	in	total	protein	following	24	hours	of	exposure.	Each	data	point	represents	
the	mean	of	three	independent	experiments,	while	error	bars	represent	the	standard	error	
of	the	mean	(SEM).	*	=	p<0.05,	**	=	p<0.01,	***	=	p<0.001	
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Figure	5:	The	FXR	agonist	GW4064	stimulates	autophagy	in	MCF-7	cells.	MCF-7	and	MDA-
MB-231	cells	were	exposed	to	3µM	GW4064	or	30	µM	CDCA	in	serum-free	medium	for	24	
hours	and	autophagy	assessed	by	(A)	LC3	cleavage	and	(B)	p62/SQSTM1	accumulation.	5mM	
3-methyladenine	and	2.5µM	rapamycin	were	included	where	indicated	as	an	inhibitor	and	
activator	of	autophagy,	respectively.	Each	data	point	represents	the	mean	of	three	
independent	experiments,	while	error	bars	represent	the	standard	error	of	the	mean	(SEM).	
*	=	p<0.05,	***	=	p<0.001	
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Figure	6:	Induction	of	apoptosis	and	autophagy	in	breast	cancer	cell	lines	by	GW6064	and	
CDCA	is	FXR-dependent.	MCF-7	and	MDA-MB-231	cells	were	exposed	to	GW4064	or	CDCA	
in	serum-free	medium	for	24	hours	in	the	presence	or	absence	of	a	dominant	negative	FXR	
protein	(FXR-DN).	(A)	Cells	were	exposed	to	3µM	GW4064	or	30	µM	CDCA		and	expression	
of	the	FXR	target	gene	SHP	monitored	by	Western	blotting.	(B)	Cells	were	exposed	to	IC50	
concentration	of	GW4064	or	CDCA	and	cell	viability	assessed	by	MTT	assay.	(C)	Cells	were	
exposed	to	3µM	GW4064	or	30	µM	CDCA	and	apoptosis	assessed	by	caspase	3/7	activity	
assay.	(D)	Cells	were	exposed	to	3µM	GW4064	or	30	µM	CDCA	and	autophagy	assessed	by	
p62/SQSTM1	accumulation.	Each	data	point	represents	the	mean	of	three	independent	
experiments,	while	error	bars	represent	the	standard	error	of	the	mean	(SEM).	*	=	p<0.05,	
**	=	p<0.01,	***	=	p<0.001	
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Figure	7:	The	FXR	agonists	GW4064	and	CDCA	do	not	stimulate	migration	of	MCF-7	or	
MDA-MB-231	cell	lines.	(A)	MCF-7	and	MDA-MB-231	cells	were	seeded	in	transwell	plates	
and	exposed	to	3µM	GW4064	or	30	µM	CDCA	in	serum-free	medium	for	72	hours.	The	
number	of	cells	migrating	into	the	bottom	chamber	was	quantified.	(B)		MCF-7	and	MDA-
MB-231	cells	were	seeded	in	a	wound-healing	assay	format	and	exposed	to	3µM	GW4064	or	
30	µM	CDCA	in	serum-free	medium	for	24	hours.	Cell	migration	was	quantified	by	closure	of	
the	scratch	area	using	the	tScatch	program.	Each	data	point	represents	the	mean	of	three	
independent	experiments,	while	error	bars	represent	the	standard	error	of	the	mean	(SEM).	
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Supplementary	Figures	
Activation	of	the	Farnesoid	X-receptor	in	breast	cancer	cell	lines	results	in	cytotoxicity	but	
not	increased	migration	potential	
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Supplementary	Figure	1:	Breast	cancer	cell	lines	express	a	functional	FXR	gene	regulatory	
network	
	
	
Figure	S1:	Breast	cancer	cell	lines	express	a	functional	FXR	gene	regulatory	network.	(A)	
MCF-10A,	MCF-7,	MDA-MB-231	and	MDA-MB-468	cells	were	exposed	to	3µM	GW4064,	
30µM	CDCA	or	vehicle	control	in	serum-free	medium	for	24	hours,	and	then	Farnesoid	X-
receptor	(FXR)	expression	assessed	by	Western	blot.	(B)	MCF-7,	MDA-MB-231	or	HepG2	
(positive	control)	cells	were	exposed	to	3µM	GW4064,	30µM	CDCA	or	vehicle	control	in	
serum-free	medium	for	24	hours,	and	then	small	heterodimer	partner	(SHP)	expression	
assessed	by	Western	blot.	Each	data	point	represents	the	mean	of	three	independent	
experiments,	while	error	bars	represent	the	standard	error	of	the	mean	(SEM).	**	=	p<0.01,	
***	=	p<0.001	
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Supplementary	Figure	S2:	The	FXR	agonists	GW4064	and	CDCA	do	not	stimulate	migration	
of	MCF-10A	or	MDA-MB-468	cell	lines	
	
	
Figure	S2:	The	FXR	agonists	GW4064	and	CDCA	do	not	stimulate	migration	of	MCF-10A	or	
MDA-MB-468	cell	lines.	(A)	MCF-10A	and	MDA-MB-468	cells	were	seeded	in	transwell	
plates	and	exposed	to	3µM	GW4064	or	30	µM	CDCA	in	serum-free	medium	for	72	hours.	
The	number	of	cells	migrating	into	the	bottom	chamber	was	quantified.	(B)		MCF-7	and	
MDA-MB-231	cells	were	seeded	in	a	wound-healing	assay	format	and	exposed	to	3µM	
GW4064	or	30	µM	CDCA	in	serum-free	medium	for	24	hours.	Cell	migration	was	quantified	
by	closure	of	the	scratch	area	using	the	tScatch	program.	Each	data	point	represents	the	
mean	of	three	independent	experiments,	while	error	bars	represent	the	standard	error	of	
the	mean	(SEM).	
	
	
